EUCTR2006-001046-13-DE进行中（未招募）不适用
Pharmacokinetic interaction study between budesonide and metronidazole in healthy volunteers
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •a)Healthy male subjects
- •b)Caucasian origin
- •c)age: between 18 and 55 years (inclusive)
- •d)body mass index (BMI) within 18-30 kg/m²
- •e)body weight at least 50 kg, at most 100 kg
- •f)non-smoker (or ex-smoker =1 year), proven by urine cotinine <500 ng/ml
- •g)clinically acceptable supine blood pressure and pulse rate, i.e. BP 100-145 mmHg systolic, 60-90 mmHg diastolic and pulse rate 50-100 bpm. Blood pressure and pulse will be measured after at least 5 minutes resting in a supine position
- •h)normal ECG
- •i)participants must perform an adequate contraception during the study and until 6 months after the last dose of the present trial
- •j)ability to communicate well with the investigator and comply with the requirements of the entire study
- •k)the subject has given his/her written consent to participate in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •a)subjects with contraindications for budesonide such as hypersensitivity to budesonide or any of the other ingredients, local infections of the intestine (bacteria, fungi, amoebae, viruses), liver cirrhosis and signs of portal hypertension (e.g., in the late stage of primary biliary cirrhosis) or subjects with tuberculosis, hypertension, diabetes mellitus, osteoporosis, peptic ulcer (gastric or duodenal ulcer), glaucoma or cataract
- •b)subjects with contraindications for metronidazole: hypersensitivity to metronidazole or other 5-nitroimidazole agents, severe hepatic disease, blood dyscrasia (prior or current history), and central or peripheral nervous system diseases
- •c)history or current clinical evidence of any cardiac, cardio-vascular, pulmonary, gastrointestinal, (cholangio-)hepatic, renal, endocrine, neurological, musculoskeletal, ophthalmological, infectious, haematological, oncological, psychiatric, or other acute or chronic diseases and/or pathological findings which might interfere with the drugs' safety, tolerability, absorption and/or pharmacokinetics
- •d)history or current evidence of clinically relevant allergies or idiosyncrasy to drugs or food
- •e)clinically relevant abnormalities in clinical chemical, hematological or any other laboratory variables
- •f)current smoker or ex-smoker =1 year
- •g)excessive alcohol consumption (³35 g/day in males and ³25 g/day in females)
- •h)abuse of drugs
- •i)positive drug screening
- •j)positive anti-HIV-test, HBsAg-test or anti-HCV-test
- •k)proneness to orthostatic dysregulation, faintings, or blackouts
- •l)heavy tea or coffee drinkers (more than 1 l ˜ 6 cups per day)
- •m)administration of glucocorticosteroids within 6 weeks prior to study day 1 or during the trial
- •n)repeated use of drugs during the last 4 weeks prior to study day 1 or during the trial, which might influence hepatic biotransformation (CYP3A inducers/inhibitors), e.g., barbiturates, cimetidine, phenytoin, rifampicin, amiodarone, clarithromycin, erythromycin, fluoxetine, fluvoxamine, ciprofloxacin, norfloxacin, fluconazole, itraconazole, ketoconazole, nefazodone, ethinylestradiol, ciclosporin, carbamazepine, corticosteroids, rifabutin, St. John’s Wort, diltiazem, verapamil, pioglitazone, modafinil
- •o)any medication including OTC medication within the last 14 days prior to study day 1 or during the trial (single intake of a drug may be accepted if judged by the investigators to have no clinical relevance and no relevance for the study objectives)
- •p)intake of grapefruit-containing food or beverages within 7 days prior to study day or during the trial
- •q)clinically relevant acute or chronic bacterial, fungal or viral infections
- •r)surgery of the gastrointestinal tract which may interfere with drug absorption (not applicable for minor abdominal surgery such as e.g. appendectomy and herniotomy)
- •s)vegetarian diet or other peculiar dietary habits which would preclude the subject’s acceptance of standardized (non-vegetarian) meals
- •t)subjects suspected or known not to follow instructions
- •u)subjects who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to as a result of their participation in the study
- •v)patients known to be in financial difficulties, which could interfere with their appraisal of the informative instructions
- •w)vulnerable subjects (e.g., persons kept in detention or persons who are depending on the sponsor or the investigator)
研究者
相似试验
已完成
不适用
Effects of the co-administration of budesonide on the plasma exposure of cabazitaxel (Jevtana??) in castrate resistant prostate cancer patientsProstate cancerNL-OMON36037Medical Oncology BV18
已完成
4 期
Pharmacokinetic Interaction Study Between Budesonide and Metronidazole in Healthy VolunteersHealthyNCT00338910University Hospital Tuebingen12
已完成
1 期
Interactions between herbal medicines and the anticoagulant warfariDrug interactions of warfarin with herbal medicines in healthy male subjects. Relevant to Stroke prevention and people receiving warfarinStroke -Other -ACTRN12607000054415Prof Andrew McLachlan60
已完成
不适用
Evaluation of Pharmacokinetic interaction between vitamin K1 and ezetimibeHealthy volunteerJPRN-UMIN000002327Department of Hospital Pharmacy, Hamamatsu University School of Medicine10
已完成
4 期
Study of the interaction between Complementary and Alternative Medicine and standard anti-cancer therapy in women with breast cancerCancer - BreastAlternative and Complementary Medicine - Other alternative and complementary medicineBreast cancerACTRN12615000673549Gregory Peterson20